Navigation Links
Omthera Announces Waiver of Lock-Up Restriction
Date:7/11/2013

mpleted pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova™. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit http://www.omthera.com.

Important Information and Where to Find It

On June 13, 2013, the Company filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement in connection with the proposed transaction (the "Definitive Proxy Statement") and, on June 14, 2013, the Company commenced mailing of the Definitive Proxy Statement to its stockholders.  INVESTORS AND THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE COMPANY.  Investors and stockholders may obtain free copies of the Definitive Proxy Statement and other documents (when available) that the Company files with the SEC at the SEC's website at http://www.sec.gov.  In addition, the Definitive Proxy Statement and other documents filed by the Company with the SEC may be obtained from the Company free of charge by directing a request to Omthera Pharmaceuticals, Inc., Attn: Christian S. Schade, Executive Vice President and Chief Financial Officer, 707 State Road, Princeton, New Jersey 08540.

Certain Information Concerning Participants

The Company and its directors and executive officers and certain other persons may be deemed to be partici
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
3. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
4. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
7. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
8. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
11. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... 29, 2015 , ... San Fernando Valley skin doctor , Dr. Peyman ... is a special treatment that offers a way to firm sagging facial and neck ... production. Ulthera is highly targeted and precise to help reduce treatment time and improve ...
(Date:6/29/2015)... ... June 29, 2015 , ... The world’s fastest and highest ... Museum to the Science Museum of Virginia. This iconic, supersonic stealth plane will become ... “Suspending a supersonic jet from the ceiling of a historic train station is perhaps ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released the ... French consumers. , The specialized eye health formulation contains a variety of ingredients ... In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, ...
(Date:6/29/2015)... ... June 29, 2015 , ... Celebrities have many skincare secrets, and ... skin all summer long and beyond. People don’t have to be famous to ... aging process, maintain an even skin tone, avoid breakouts, and take skin health and ...
(Date:6/29/2015)... ... 29, 2015 , ... Blue Cross and Blue Shield of ... Markets division, which includes the company’s commercial health plan portfolio of products and ... and international reach. Mary Ellen Anderson now holds the title of vice president, ...
Breaking Medicine News(10 mins):Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3
... The level of interest toddlers with early signs of autism ... to a parent-guided treatment program, a new study suggests. ... age 2 who met the criteria for autism disorders. The ... control group) or enrolled in the Hanen,s More Than Words ...
... University Research Chair Peter Shizgal who investigates the ... been recognized by his peers with the prestigious Prix ... of Psychology and a member of the Centre for ... Socit qubcoise pour la recherche en psychologie (Quebec Society ...
... (HealthDay News) -- Children with epilepsy are at increased risk ... the types of psychiatric problems they develop, a new study ... aged 8 to 13, and found that 111 children (0.8 ... a much higher rate of psychiatric symptoms (38 percent) than ...
... , FRIDAY, March 25 (HealthDay News) -- A poor ... among postmenopausal women, a new study has found. Researchers ... and found that deficiencies in more than a single nutrient ... anemia. Risk increased 44 percent with deficiencies in three nutrients. ...
... Association for Cancer Research is awarding 50 Minority Scholar ... Meeting 2011, held April 2-6. The award, now in ... and training of minority researchers and increase the visibility ... provides funds for the participation of early-career, meritorious minority ...
... Fla. The AACR would like to congratulate its ... 2011, held April 2-6. Grant details and recipients ... AACR-Amgen, Inc. Fellowships in Clinical/Translational Cancer Research , Takashi ... targets in invasive bladder cancer, Kun Wang, Ph.D., University ...
Cached Medicine News:Health News:Interest in Toys May Predict Success of Autism Home Therapy 2Health News:Peter Shizgal distinguished by his peers 2Health News:Gender May Play Role in Psych Symptoms in Kids With Epilepsy 2Health News:Poor Eating Habits May Lead to Anemia in Older Women 2Health News:AACR awards 50 minority scholar in cancer research awards 2Health News:AACR awards 50 minority scholar in cancer research awards 3Health News:AACR awards 50 minority scholar in cancer research awards 4Health News:AACR awards 50 minority scholar in cancer research awards 5Health News:AACR awards 50 minority scholar in cancer research awards 6Health News:AACR awards 50 minority scholar in cancer research awards 7Health News:AACR recognizes its newest grantees at 102nd Annual Meeting 2011 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: